Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAbstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Updated appropriate use criteria for amyloid and tau PET.
10.1002/alz.078912 · 2023
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-ß plaques: a prospective cohort study.
10.1016/s1474-4422(12)70142-4 · 2012
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study.
10.1016/j.jalz.2015.02.004 · 2015
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease.
10.1016/j.dadm.2017.06.001 · 2017
Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology.
10.1002/alz.13883 · 2024
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.
10.1016/j.jalz.2014.07.003 · 2015
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.
10.1016/j.nicl.2025.103765 · 2025
Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study.
10.2967/jnumed.124.268119 · 2025
Amyloid PET quantitation and Centiloid thresholds in the diagnosis of Alzheimer disease: an individual participant data meta-analysis.
10.1001/jama.2026.13116 · 2026
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.
10.1002/alz.14336 · 2024
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease.
10.1186/s13195-020-00587-5 · 2020
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology.
10.1016/j.jalz.2018.09.001 · 2019
Concordance between amyloid-PET quantification and real-world visual reads.
10.1001/jamaneurol.2025.2218 · 2025
Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study.
10.1212/wnl.0000000000200287 · 2022
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies.
10.1002/alz.70997 · 2025
Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup.
10.1002/alz.13859 · 2024
No additional external references are available.